<DOC>
	<DOCNO>NCT00003260</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give drug different combination may kill tumor cell . It yet know whether receive irinotecan fluorouracil leucovorin effective receive oxaliplatin fluorouracil leucovorin treat recurrent metastatic colorectal cancer PURPOSE : Randomized phase III trial compare effectiveness irinotecan oxaliplatin follow fluorouracil leucovorin treat patient recurrent metastatic colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Recurrent Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy leucovorin calcium plus fluorouracil either irinotecan oxaliplatin term progression free survival patient recurrent metastatic colorectal cancer . II . Compare efficacy , tolerance , quality life , overall survival patient population . OUTLINE : This randomize , multicenter study . Patients stratify participate institution measurable evaluable disease . Patients randomize receive either 2 hour continuous infusion irinotecan 2 hour continuous infusion oxaliplatin day 1 . All patient receive 2 hour continuous infusion leucovorin calcium follow IV bolus 48 hour continuous infusion fluorouracil day 1 2 . Courses repeat every 2 week . Patients receive alternate treatment disease progression unacceptable toxicity occur initial treatment . Patients follow every 3 month end treatment . PROJECTED ACCRUAL : This study accrue total 109 patient per arm approximately 18 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove recurrent stage IV adenocarcinoma colon rectum No CNS metastases Bidimensionally measurable lesion ( least 2 cm dimension ) evaluable disease ( malignant ascites bone metastasis ) document CT MRI Must outside prior radiotherapy field PATIENT CHARACTERISTICS : Age : 18 75 Performance status : WHO 02 Life expectancy : Greater 3 month Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal Alkaline phosphatase great 3 time normal SGOT/SGPT great 3 time normal Renal : Creatinine great 1.5 mg/dL Cardiovascular : No uncontrolled congestive heart failure angina pectoris past 6 month No hypertension arrhythmia past 6 month Neurologic : No peripheral neuropathy No significant neurologic psychiatric disorder Other : No complete partial obstruction bowel No serious nonmalignant disease No active infection No second malignancy except situ cervical carcinoma nonmelanomatous skin carcinoma No chronic diarrhea Not pregnant nursing Fertile woman must use adequate contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy metastatic disease Chemotherapy : No prior chemotherapy metastatic disease At least 6 month since prior adjuvant chemotherapy disease progression metastatic liver resection No prior chemotherapy oxaliplatin irinotecan Endocrine therapy : Not specify Radiotherapy : At least 2 week since prior radiotherapy Surgery : At least 2 week since surgery Other : At least 30 day since use investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>